SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2011 - 2026)
SELLAS Life Sciences' (SLS) quarterly Net Income towards Common Stockholders came in at -$15.1 million in Q1 2026, down 140.35% year-on-year from $37.3 million in Q1 2025, and down 80.17% on a QoQ basis from -$8.4 million in Q4 2025.
SELLAS Life Sciences (SLS) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$15.1 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 140.35% year-over-year to -$15.1 million in Q1 2026; TTM through Mar 2026 was -$39.6 million, a 39.35% decrease from a year earlier, with the FY2025 full-year figure at -$51.1 million, up 2.42% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$15.1 million, down from -$8.4 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for SLS reached as high as -$6.3 million in Q1 2025 and fell as low as -$16.8 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$9.3 million across 5 years, with a median of -$8.7 million in 2022.
- Across the five-year window, Net Income towards Common Stockholders tumbled 600.58% in 2022 and jumped 35.73% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$9.6 million in 2022, then grew by 14.19% to -$8.3 million in 2023, then gained by 15.21% to -$7.0 million in 2024, then retreated by 19.05% to -$8.4 million in 2025, then tumbled by 80.17% to -$15.1 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$15.1 million in Q1 2026, -$8.4 million in Q4 2025, and -$7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | SELLAS Life Sciences | 1.89 Bn | 1.78 Bn | - | -15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.05 Mn |
| Dec 31, 2025 | -8.36 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -8.93 Mn |
| Mar 31, 2025 | -6.26 Mn |
| Dec 31, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.43 Mn |
| Jun 30, 2024 | -7.72 Mn |
| Mar 31, 2024 | -9.75 Mn |
| Dec 31, 2023 | -8.28 Mn |
| Sep 30, 2023 | -9.46 Mn |
| Jun 30, 2023 | -9.15 Mn |
| Mar 31, 2023 | -11.38 Mn |
| Dec 31, 2022 | -9.65 Mn |
| Sep 30, 2022 | -7.25 Mn |
| Jun 30, 2022 | -8.72 Mn |
| Mar 31, 2022 | -16.84 Mn |
| Dec 31, 2021 | -6.60 Mn |
| Sep 30, 2021 | -7.09 Mn |
| Jun 30, 2021 | -4.61 Mn |